Glaxo enters the dollar bond market

GlaxoSmithKline, the blue-chip UK pharmaceutical company which is a rare borrower in the debt markets, has raised $2.5bn (€2.1bn) with a debut benchmark offering in the dollar bond market.

Citigroup, whose subsidiary Schroder Salomon Smith Barney arranged GSK's £5bn debt issuance programme in December 2001, and JP Morgan and Lehman Brothers, two of the dealer banks on that programme, led the dollar bond.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump